Qiagen (NYSE:QGEN) Shares Acquired by Parkman Healthcare Partners LLC

Parkman Healthcare Partners LLC boosted its stake in Qiagen (NYSE:QGEN) by 31.6% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 277,272 shares of the company’s stock after purchasing an additional 66,503 shares during the period. Qiagen accounts for 1.6% of Parkman Healthcare Partners LLC’s holdings, making the stock its 22nd biggest holding. Parkman Healthcare Partners LLC’s holdings in Qiagen were worth $12,347,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Barclays PLC increased its holdings in shares of Qiagen by 170.6% in the third quarter. Barclays PLC now owns 1,849,004 shares of the company’s stock valued at $84,259,000 after buying an additional 1,165,594 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in shares of Qiagen by 34.7% during the 4th quarter. Assenagon Asset Management S.A. now owns 16,409 shares of the company’s stock worth $731,000 after purchasing an additional 4,225 shares in the last quarter. Park Avenue Securities LLC increased its stake in shares of Qiagen by 32.1% during the 4th quarter. Park Avenue Securities LLC now owns 8,908 shares of the company’s stock worth $397,000 after purchasing an additional 2,166 shares during the last quarter. MassMutual Private Wealth & Trust FSB raised its holdings in Qiagen by 83.5% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,565 shares of the company’s stock valued at $70,000 after buying an additional 712 shares in the last quarter. Finally, Ballentine Partners LLC bought a new stake in shares of Qiagen during the 4th quarter worth $241,000. Institutional investors own 70.00% of the company’s stock.

Qiagen Stock Down 2.0%

Shares of NYSE QGEN opened at $42.08 on Wednesday. The company has a quick ratio of 3.09, a current ratio of 3.61 and a debt-to-equity ratio of 0.38. The firm’s fifty day moving average is $40.80 and its 200 day moving average is $41.78. The company has a market cap of $9.35 billion, a price-to-earnings ratio of 117.17, a PEG ratio of 2.39 and a beta of 0.67. Qiagen has a 52 week low of $37.63 and a 52 week high of $49.30.

Qiagen (NYSE:QGEN) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of $0.50 by $0.05. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. The business had revenue of $483.46 million for the quarter, compared to the consensus estimate of $465.66 million. During the same period last year, the firm earned $0.44 earnings per share. The company’s quarterly revenue was up 5.2% on a year-over-year basis. On average, equities research analysts expect that Qiagen will post 2.26 earnings per share for the current year.

Wall Street Analyst Weigh In

QGEN has been the subject of several research reports. Robert W. Baird raised their target price on Qiagen from $42.00 to $43.00 and gave the stock a “neutral” rating in a research report on Monday, April 21st. StockNews.com raised Qiagen from a “buy” rating to a “strong-buy” rating in a report on Friday, May 9th. UBS Group decreased their price objective on Qiagen from $50.00 to $48.00 and set a “neutral” rating on the stock in a research report on Friday, February 7th. Redburn Atlantic lowered shares of Qiagen from a “buy” rating to a “neutral” rating in a report on Friday, April 4th. Finally, Baird R W cut Qiagen from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 19th. Seven investment analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Qiagen currently has an average rating of “Hold” and an average target price of $48.42.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.